Grand Pharma Acquired 100% Equity of Hubei Bafeng, Further Expanding the Strategic Plan on High-quality Amino Acid Industry
- Written by Viw Magazine
- Hubei Bafeng is one of the national pharmaceutical amino acid industrialization bases in China, with over 20 drug approval numbers;
- After the acquisition is completed, Grand Pharma will become the pharmaceutical company with the most registration numbers of amino acid APIs in China;
- Grand Pharma's amino acid industry has leading technological advantages, and its products are sold to more than 140 countries and regions around the world.
